Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Daniel A Arber, Attilio Orazi, Robert P Hasserjian, Michael J Borowitz, Katherine R Calvo, Hans-Michael Kvasnicka, Sa A Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E Bueso-Ramos, Jorge E Cortes, Paola Dal Cin, Courtney D DiNardo, Hervé Dombret, Eric J Duncavage, Benjamin L Ebert, Elihu H Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S Hobbs, Ronald Hoffman, Elias J Jabbour, Jean-Jacques Kiladjian, Richard A Larson, Michelle M Le Beau, Mignon L-C Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G Mullighan, Charlotte Niemeyer, Olatoyosi M Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R Savona, Charles A Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A Stock, Richard M Stone, Martin S Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M Vannucchi, Paresh Vyas, Andrew H Wei, Olga K Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification...
September 15, 2022: Blood
#22
JOURNAL ARTICLE
Malin Hultcrantz, Even H Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M Lesokhin, Hani Hassoun, Eric L Smith, Oscar B Lahoud, Heather J Landau, Gunjan L Shah, Michael Scordo, David J Chung, Sergio Giralt, Elli Papaemmanuil, Ola Landgren
PURPOSE: Minimal residual disease (MRD) negativity is a strong predictor for outcome in multiple myeloma. To assess V(D)J clonotype capture using the updated Adaptive next-generation sequencing (NGS) MRD assay in a clinical setting, we analyzed baseline and follow-up samples from patients with multiple myeloma who achieved deep clinical responses. EXPERIMENTAL DESIGN: A total of 159 baseline and 31 follow-up samples from patients with multiple myeloma were sequenced using the NGS MRD assay...
May 13, 2022: Clinical Cancer Research
#23
JOURNAL ARTICLE
Barbara Spitzer, Kayleigh D Rutherford, Gunes Gundem, Erin M McGovern, Nathan E Millard, Juan E Arango Ossa, Irene Y Cheung, Teng Gao, Max F Levine, Yanming Zhang, Juan S Medina-Martínez, Yi Feng, Ryan N Ptashkin, Kelly L Bolton, Noushin Farnoud, Yangyu Zhou, Minal A Patel, Georgios Asimomitis, Cassidy C Cobbs, Neeman Mohibullah, Kety H Huberman, Maria E Arcilla, Brian H Kushner, Shakeel Modak, Andrew L Kung, Ahmet Zehir, Ross L Levine, Scott A Armstrong, Nai Kong V Cheung, Elli Papaemmanuil
PURPOSE: Therapy-related myelodysplastic syndrome and acute leukemias (t-MDS/AL) are a major cause of nonrelapse mortality among pediatric cancer survivors. Although the presence of clonal hematopoiesis (CH) in adult patients at cancer diagnosis has been implicated in t-MDS/AL, there is limited published literature describing t-MDS/AL development in children. EXPERIMENTAL DESIGN: We performed molecular characterization of 199 serial bone marrow samples from 52 patients treated for high-risk neuroblastoma, including 17 with t-MDS/AL (transformation), 14 with transient cytogenetic abnormalities (transient), and 21 without t-MDS/AL or cytogenetic alterations (neuroblastoma-treated control)...
April 14, 2022: Clinical Cancer Research
#24
JOURNAL ARTICLE
Georgios Asimomitis, André G Deslauriers, Andriana G Kotini, Elsa Bernard, Davide Esposito, Malgorzata Olszewska, Nikolaos Spyrou, Juan Esteban Arango Ossa, Teresa Mortera-Blanco, Richard Patrick Koche, Yasuhito Nannya, Luca Malcovati, Seishi Ogawa, Mario Cazzola, Stuart A Aaronson, Eva Hellström-Lindberg, Elli Papaemmanuil, Eirini P Papapetrou
SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E and SF3B1WT induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA- and ATAC- sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells...
January 18, 2022: Blood Advances
#25
JOURNAL ARTICLE
Thomas Creasey, Emilio Barretta, Sarra L Ryan, Ellie Butler, Amy A Kirkwood, Daniel Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias Menne, Andrew K McMillan, Christine J Harrison, Clare J Rowntree, Nick Morley, David I Marks, Adele K Fielding, Anthony V Moorman
Despite being predominantly a childhood disease, the incidence of acute lymphoblastic leukemia (ALL) has a second peak in adults aged 60 years and over. These older adults fare extremely poorly with existing treatment strategies and very few studies have undertaken a comprehensive genetic and genomic characterization to improve prognosis in this age group. We performed cytogenetic, single nucleotide polymorphism (SNP) array and next-generation sequencing (NGS) analyses on samples from 210 patients aged ≥60 years from the UKALL14 and UKALL60+ clinical trials...
September 1, 2022: Haematologica
#26
MULTICENTER STUDY
Julie M Cunningham, Stacey J Winham, Chen Wang, Britta Weiglt, Zhuxuan Fu, Sebastian M Armasu, Bryan M McCauley, Alison H Brand, Yoke-Eng Chiew, Esther Elishaev, Charlie Gourley, Catherine J Kennedy, Angela Laslavic, Jenny Lester, Anna Piskorz, Magdalena Sekowska, James D Brenton, Michael Churchman, Anna DeFazio, Ronny Drapkin, Kevin M Elias, David G Huntsman, Beth Y Karlan, Martin Köbel, Jason Konner, Kate Lawrenson, Elli Papaemmanuil, Kelly L Bolton, Francesmary Modugno, Ellen L Goode
BACKGROUND: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. METHODS: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways...
January 2022: Cancer Epidemiology, Biomarkers & Prevention
#27
JOURNAL ARTICLE
Anthony V Moorman, Emilio Barretta, Ellie R Butler, Eleanor J Ward, Katie Twentyman, Amy A Kirkwood, Amir Enshaei, Claire Schwab, Tom Creasey, Daniel Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias Menne, Andrew K McMillan, Christine J Harrison, Clare J Rowntree, David I Marks, Adele K Fielding
Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor ALL treated on a modern MRD driven protocol. Patients with KMT2A-AFF1, complex karyotype (CK) and low hypodiploidy/near-triploidy (HoTr) had high relapse rates 50%, 60% & 53% and correspondingly poor survival. Patients with BCR-ABL1 had an outcome similar to other patients. JAK-STAT abnormalities (CRLF2, JAK2) occurred in 6% patients and were associated with a high relapse rate (56%)...
March 2022: Leukemia
#28
JOURNAL ARTICLE
Kelly L Bolton, Youngil Koh, Michael B Foote, Hogune Im, Justin Jee, Choong Hyun Sun, Anton Safonov, Ryan Ptashkin, Joon Ho Moon, Ji Yeon Lee, Jongtak Jung, Chang Kyung Kang, Kyoung-Ho Song, Pyoeng Gyun Choe, Wan Beom Park, Hong Bin Kim, Myoung-Don Oh, Han Song, Sugyeong Kim, Minal Patel, Andriy Derkach, Erika Gedvilaite, Kaitlyn A Tkachuk, Brian J Wiley, Ireaneus C Chan, Lior Z Braunstein, Teng Gao, Elli Papaemmanuil, N Esther Babady, Melissa S Pessin, Mini Kamboj, Luis A Diaz, Marc Ladanyi, Michael J Rauh, Pradeep Natarajan, Mitchell J Machiela, Philip Awadalla, Vijai Joseph, Kenneth Offit, Larry Norton, Michael F Berger, Ross L Levine, Eu Suk Kim, Nam Joong Kim, Ahmet Zehir
Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced age, increased risk of cardiovascular and malignant diseases, and decreased overall survival. These adverse sequelae may be mediated by altered inflammatory profiles observed in patients with CH. A pro-inflammatory immunologic profile is also associated with worse outcomes of certain infections, including SARS-CoV-2 and its associated disease Covid-19. Whether CH predisposes to severe Covid-19 or other infections is unknown...
October 13, 2021: Nature Communications
#29
JOURNAL ARTICLE
Ellen M Beauchamp, Matthew Leventhal, Elsa Bernard, Emma R Hoppe, Gabriele Todisco, Maria Creignou, Anna Gallì, Cecilia A Castellano, Marie McConkey, Akansha Tarun, Waihay Wong, Monica Schenone, Caroline Stanclift, Benjamin Tanenbaum, Edyta Malolepsza, Björn Nilsson, Alexander G Bick, Joshua S Weinstock, Mendy Miller, Abhishek Niroula, Andrew Dunford, Amaro Taylor-Weiner, Timothy Wood, Alex Barbera, Shankara Anand, Bruce M Psaty, Pinkal Desai, Michael H Cho, Andrew D Johnson, Ruth Loos, Daniel G MacArthur, Monkol Lek, Donna S Neuberg, Kasper Lage, Steven A Carr, Eva Hellstrom-Lindberg, Luca Malcovati, Elli Papaemmanuil, Chip Stewart, Gad Getz, Robert K Bradley, Siddhartha Jaiswal, Benjamin L Ebert
Clonal hematopoiesis results from somatic mutations in cancer driver genes in hematopoietic stem cells. We sought to identify novel drivers of clonal expansion using an unbiased analysis of sequencing data from 84,683 persons and identified common mutations in the 5-methylcytosine reader, ZBTB33 , as well as in YLPM1 , SRCAP , and ZNF318 . We also identified these mutations at low frequency in myelodysplastic syndrome patients. Zbtb33 edited mouse hematopoietic stem and progenitor cells exhibited a competitive advantage in vivo and increased genome-wide intron retention...
September 2021: Blood cancer discovery
#30
JOURNAL ARTICLE
Eileen Wedge, Jakob Werner Hansen, Ingunn Dybedal, Maria Creignou, Elisabeth Ejerblad, Fryderyk Lorenz, Olle Werlenius, Johanna Ungerstedt, Mette Skov Holm, Lars Nilsson, Astrid Olsnes Kittang, Peter Antunovic, Peter Rohon, Mette Klarskov Andersen, Elli Papaemmanuil, Elsa Bernard, Martin Jädersten, Eva Hellström-Lindberg, Kirsten Grønbæk, Per Ljungman, Lone Smidstrup Friis
BACKGROUND: Chronic myelomonocytic leukemia (CMML) is an aggressive disease in which survival after allogeneic hematopoietic stem cell transplantation (HCT) remains relatively poor. An assessment of prognostic factors is an important part of treatment decision-making and has the potential to be greatly improved by the inclusion of molecular genetics. However, there is a significant knowledge gap in the interpretation of mutational patterns. OBJECTIVE: This study aimed to describe outcomes from allogeneic HCT in CMML in relation to clinical and molecular genetic risk factors...
September 6, 2021: Transplantation and cellular therapy
#31
JOURNAL ARTICLE
Rachel J Mitchell, Amy A Kirkwood, Emilio Barretta, Laura Clifton-Hadley, Emma Lawrie, SooWah Lee, Daniel Leongamornlert, David I Marks, Andrew K McMillan, Tobias F Menne, Elli Papaemmanuil, Bela Patel, Pip Patrick, Clare J Rowntree, Nahid Zareian, Krisztina Zuborne Alapi, Anthony V Moorman, Adele K Fielding
IKZF1 deletions (ΔIKZF1) are commonly detected in B-precursor acute lymphoblastic leukemia (ALL; B-ALL) and are widely assumed to have a significant impact on outcome. We compared the ability of multiplex ligand-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) to detect ΔIKZF1 and to determine the impact on event-free survival of patients with precursor B-ALL aged 23 to 65 years recruited to the completed trial UKALL14 (ISRCTN 66541317). From 655 recruits with BCR-ABL1+ and BCR-ABL1- B-ALL, all available diagnostic DNA samples (76% of the recruited population) were screened by multiplex end point PCR covering 4 deletions: dominant-negative (DN) Δ4-7 or the loss of function Δ2-7, Δ4-8, and Δ2-8 (n = 498), MLPA (n = 436), or by both (n = 420)...
September 14, 2021: Blood Advances
#32
JOURNAL ARTICLE
Karam T Alhalabi, Damian Stichel, Philipp Sievers, Heike Peterziel, Alexander C Sommerkamp, Dominik Sturm, Andrea Wittmann, Martin Sill, Natalie Jäger, Pengbo Beck, Kristian W Pajtler, Matija Snuderl, George Jour, Michael Delorenzo, Allison M Martin, Adam Levy, Nagma Dalvi, Jordan R Hansford, Nicholas G Gottardo, Emmanuelle Uro-Coste, Claude-Alain Maurage, Catherine Godfraind, Fanny Vandenbos, Torsten Pietsch, Christof Kramm, Maria Filippidou, Antonis Kattamis, Chris Jones, Ingrid Øra, Torben Stamm Mikkelsen, Michal Zapotocky, David Sumerauer, David Scheie, Martin McCabe, Pieter Wesseling, Bastiaan B J Tops, Mariëtte E G Kranendonk, Matthias A Karajannis, Nancy Bouvier, Elli Papaemmanuil, Hildegard Dohmen, Till Acker, Katja von Hoff, Simone Schmid, Evelina Miele, Katharina Filipski, Lidija Kitanovski, Lenka Krskova, Johannes Gojo, Christine Haberler, Frank Alvaro, Jonas Ecker, Florian Selt, Till Milde, Olaf Witt, Ina Oehme, Marcel Kool, Andreas von Deimling, Andrey Korshunov, Stefan M Pfister, Felix Sahm, David T W Jones
Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone...
November 2021: Acta Neuropathologica
#33
JOURNAL ARTICLE
Sanam Shahid, Brian H Kushner, Shakeel Modak, Ellen M Basu, Elyssa M Rubin, Gunes Gundem, Elli Papaemmanuil, Stephen S Roberts
Very rarely, vasoactive intestinal peptide-related diarrhea (VIP-D) is observed in patients with high-risk neuroblastoma (HR-NB) where the associated fluid and electrolyte abnormalities can pose a major clinical challenge for administering the required aggressive multimodality treatment. Two patients with HR-NB developed VIP-D during induction and were found to have a somatic BRAF V600E mutation. Serum VIP levels and diarrhea promptly resolved in both patients after initiating treatment with BRAF and MEK inhibitors...
October 2021: Pediatric Blood & Cancer
#34
JOURNAL ARTICLE
Catherine C Smith, Aaron D Viny, Evan Massi, Cyriac Kandoth, Nicholas D Socci, Franck Rapaport, Matthieu Najm, Juan S Medina-Martinez, Elli Papaemmanuil, Theodore C Tarver, Henry H Hsu, Mai H Le, Brian West, Gideon Bollag, Barry S Taylor, Ross L Levine, Neil P Shah
PURPOSE: Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical response to the novel FLT3 inhibitor pexidartinib (PLX3397). EXPERIMENTAL DESIGN: We performed targeted sequencing of pretreatment blasts from 29 patients with FLT3 internal tandem duplication (ITD) mutations treated on the phase I/II trial of pexidartinib in relapsed/refractory FLT3 -ITD+ acute myeloid leukemia (AML)...
July 15, 2021: Clinical Cancer Research
#35
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Juan S Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F Levine, Juan E Arango, Yangyu Zhou, Francesc Solé, Catherine A Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan A van de Loosdrecht, Martin Jädersten, Magnus Tobiasson, Olivier Kosmider, Matilde Y Follo, Felicitas Thol, Ronald F Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P S Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John M Bennett, Virginia M Klimek, Michael R Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Harold K Elias, Alexandra G Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna S Neuberg, Kristen E Stevenson, Kamal Menghrajani, Kelly L Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L Ebert, Rafael Bejar, Peter L Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil
No abstract text is available yet for this article.
May 4, 2021: Nature Medicine
#36
JOURNAL ARTICLE
Eleftheria Lamprianidou, Chryssoula Kordella, Anastasiya Kazachenka, Emmanouela Zoulia, Elsa Bernard, Anastasia Filia, Stamatia Laidou, Panayiotis Garantziotis, Theodoros P Vassilakopoulos, Sotirios G Papageorgiou, Vassiliki Pappa, Athanasios G Galanopoulos, Nora Viniou, Evangelia Nakou, Lydia Kalafati, Anastasia Chatzidimitriou, George Kassiotis, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis
CD4+ T cells orchestrate immune responses and are actively engaged in shaping tumor immunity. Signal transducer and activator of transcription (STAT) signaling controls the epigenetic tuning of CD4+ T-cell differentiation and polarization, and perturbed STAT signaling networks in CD4+ T cells subvert antitumor immunity in malignancies. Azacitidine (AZA), the mainstay therapy for high-risk myelodysplastic syndromes (HR-MDS), affects CD4+ T-cell polarization and function, but whether this contributes to AZA efficacy is currently unknown...
January 12, 2021: Blood Advances
#37
Elsa Bernard, Yasuhito Nannya, Robert P Hasserjian, Sean M Devlin, Heinz Tuechler, Juan S Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max F Levine, Juan E Arango, Yangyu Zhou, Francesc Solé, Catherine A Cargo, Detlef Haase, Maria Creignou, Ulrich Germing, Yanming Zhang, Gunes Gundem, Araxe Sarian, Arjan A van de Loosdrecht, Martin Jädersten, Magnus Tobiasson, Olivier Kosmider, Matilde Y Follo, Felicitas Thol, Ronald F Pinheiro, Valeria Santini, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio P S Santos, Julie Schanz, Senji Kasahara, Takayuki Ishikawa, Hisashi Tsurumi, Akifumi Takaori-Kondo, Toru Kiguchi, Chantana Polprasert, John M Bennett, Virginia M Klimek, Michael R Savona, Monika Belickova, Christina Ganster, Laura Palomo, Guillermo Sanz, Lionel Ades, Matteo Giovanni Della Porta, Alexandra G Smith, Yesenia Werner, Minal Patel, Agnès Viale, Katelynd Vanness, Donna S Neuberg, Kristen E Stevenson, Kamal Menghrajani, Kelly L Bolton, Pierre Fenaux, Andrea Pellagatti, Uwe Platzbecker, Michael Heuser, Peter Valent, Shigeru Chiba, Yasushi Miyazaki, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Michaela Fontenay, Joop H Jansen, José Cervera, Yoshiko Atsuta, Norbert Gattermann, Benjamin L Ebert, Rafael Bejar, Peter L Greenberg, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Elli Papaemmanuil
No abstract text is available yet for this article.
March 2021: Nature Medicine
#38
JOURNAL ARTICLE
Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, Andriy Derkach, Venkata D Yellapantula, Even H Rustad, Malin Hultcrantz, Urvi A Shah, Jessica Hong, Heather J Landau, Christine A Iacobuzio-Donahue, Elli Papaemmanuil, Shani Irby, Laura Crowley, Michael Crane, Mayris P Webber, David G Goldfarb, Rachel Zeig-Owens, Orsi Giricz, Amit Verma, David J Prezant, Ahmet Dogan, Sohrab P Shah, Yanming Zhang, Ola Landgren
PURPOSE: The World Trade Center (WTC) attack of September 11, 2001 created an unprecedented environmental exposure to known and suspected carcinogens. High incidence of multiple myeloma and precursor conditions has been reported among first responders to the WTC disaster. To expand on our prior screening studies, and to characterize the genomic impact of the exposure to known and potential carcinogens in the WTC debris, we were motivated to perform whole-genome sequencing (WGS) of WTC first responders and recovery workers who developed a plasma cell disorder after the attack...
April 1, 2021: Clinical Cancer Research
#39
Heather J Landau, Venkata Yellapantula, Benjamin T Diamond, Even H Rustad, Kylee H Maclachlan, Gunes Gundem, Juan Medina-Martinez, Juan Arango Ossa, Max F Levine, Yangyu Zhou, Rajya Kappagantula, Priscilla Baez, Marc Attiyeh, Alvin Makohon-Moore, Lance Zhang, Eileen M Boyle, Cody Ashby, Patrick Blaney, Minal Patel, Yanming Zhang, Ahmet Dogan, David J Chung, Sergio Giralt, Oscar B Lahoud, Jonathan U Peled, Michael Scordo, Gunjan Shah, Hani Hassoun, Neha S Korde, Alexander M Lesokhin, Sydney Lu, Sham Mailankody, Urvi Shah, Eric Smith, Malin L Hultcrantz, Gary A Ulaner, Frits van Rhee, Gareth J Morgan, Ola Landgren, Elli Papaemmanuil, Christine Iacobuzio-Donahue, Francesco Maura
No abstract text is available yet for this article.
January 20, 2021: Nature Communications
#40
JOURNAL ARTICLE
Teng Gao, Ryan Ptashkin, Kelly L Bolton, Maria Sirenko, Christopher Fong, Barbara Spitzer, Kamal Menghrajani, Juan E Arango Ossa, Yangyu Zhou, Elsa Bernard, Max Levine, Juan S Medina Martinez, Yanming Zhang, Sebastià Franch-Expósito, Minal Patel, Lior Z Braunstein, Daniel Kelly, Mariko Yabe, Ryma Benayed, Nicole M Caltabellotta, John Philip, Ederlinda Paraiso, Simon Mantha, David B Solit, Luis A Diaz, Michael F Berger, Virginia Klimek, Ross L Levine, Ahmet Zehir, Sean M Devlin, Elli Papaemmanuil
Stably acquired mutations in hematopoietic cells represent substrates of selection that may lead to clonal hematopoiesis (CH), a common state in cancer patients that is associated with a heightened risk of leukemia development. Owing to technical and sample size limitations, most CH studies have characterized gene mutations or mosaic chromosomal alterations (mCAs) individually. Here we leverage peripheral blood sequencing data from 32,442 cancer patients to jointly characterize gene mutations (n = 14,789) and mCAs (n = 383) in CH...
January 12, 2021: Nature Communications
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
